IL5 and lung carcinoma: reports that IL-33 treatment enhances ILC2 IL-5 immune response in the lung, thus activating eosinophils that subsequently suppress vital, anti-tumor Th-1 immunity, and lending to increased lung cancer metastasis and mortality (36).